If you have a history of skin cancer—whether basal cell carcinoma, squamous cell carcinoma, or melanoma—you may be understandably cautious about any treatment involving ultraviolet light. 308nm targeted phototherapy (excimer laser or LED) is highly effective for psoriasis and vitiligo, but its safety in skin cancer survivors depends on several factors. Here’s what you need to know before considering treatment.

How 308nm Light Differs from Natural Sunlight

The 308nm wavelength falls within the UVB spectrum. Unlike UVA or broad‑spectrum UV, it does not penetrate as deeply and is delivered in a focused, controlled manner. However, any UV exposure carries a theoretical risk of DNA damage and skin cancer promotion, especially in individuals with a personal history of skin cancer.

Key Considerations for Skin Cancer Survivors

1. Type of Skin Cancer History Matters

Non‑melanoma skin cancers (basal cell, squamous cell): In patients with a history of localized, non‑aggressive NMSC, dermatologists may consider 308nm phototherapy if the treatment area is distant from the prior cancer site and the patient has no signs of field cancerization (multiple actinic keratoses). Strict sun protection and regular skin checks are mandatory.
Melanoma: A history of melanoma is generally considered a relative contraindication to any UV‑based phototherapy, including 308nm. Because the risk of UV‑induced melanocytic transformation is uncertain, most dermatologists avoid treating patients with a personal history of melanoma unless there are compelling reasons and no alternative therapies exist.

2. Location of Treatment vs. Prior Cancer

Treating a site unrelated to the previous skin cancer (e.g., using 308nm on the hands when a prior BCC was on the nose) carries lower theoretical risk than treating an area within the same field of sun damage. If the planned treatment area shows actinic keratoses or significant photoaging, phototherapy may be discouraged.

3. Alternative Treatments Should Be Exhausted First

For patients with a skin cancer history, dermatologists typically reserve 308nm phototherapy for cases where:

Topical therapies (corticosteroids, calcineurin inhibitors, vitamin D analogues) have failed or are not tolerated.
Systemic therapies (biologics, oral medications) are either not indicated or the patient prefers to avoid them.
The condition (psoriasis or vitiligo) significantly impacts quality of life.

What the Research Says

There are no large‑scale studies specifically evaluating 308nm phototherapy in patients with a history of skin cancer. However, decades of experience with narrowband UVB (311–313 nm) suggest that the risk of non‑melanoma skin cancer is low but not zero, especially with cumulative high doses. The 308nm excimer laser delivers lower total cumulative UV exposure than whole‑body NB‑UVB because it treats only diseased skin. This may theoretically reduce overall risk, but the same biological principle applies: UV is a known carcinogen.

Precautions If Treatment Is Pursued

If a dermatologist determines that 308nm phototherapy is appropriate for you despite a history of skin cancer, strict precautions must be followed:

Full skin examination before starting and every 3–6 months during treatment.
Treat only affected areas—no “prophylactic” treatment of normal skin.
Shield all non‑target areas to avoid unnecessary UV exposure.
Use the lowest effective dose (minimal erythema dose approach).
Avoid combining with photosensitizing medications that could increase risk.
Meticulous sun protection (SPF 50+, protective clothing) on all exposed skin, including treated areas.

The Bottom Line

For patients with a history of non‑melanoma skin cancer and no evidence of widespread actinic damage, 308nm phototherapy may be considered on a case‑by‑case basis, provided the treatment area is distinct from prior cancer sites and alternative therapies have been inadequate. For patients with a history of melanoma, most dermatologists advise against UV‑based phototherapy due to safety concerns.

Never begin 308nm phototherapy without a thorough evaluation by a board‑certified dermatologist who knows your complete skin cancer history. Together, you can weigh the benefits against the risks and explore all treatment options.

If you have a history of skin cancer, your safety comes first. There are often effective non‑UV alternatives—including topical immunomodulators, vitamin D analogues, and systemic agents—that can manage psoriasis and vitiligo without the theoretical risk associated with phototherapy.

Can You Use 308nm Phototherapy if You Have a History of Skin Cancer?

Get the latest price?